152 related articles for article (PubMed ID: 21172078)
21. Retrospective study of neoadjuvant versus adjuvant radiochemotherapy in locally advanced noninflammatory breast cancer : survival advantage in cT2 category by neoadjuvant radiochemotherapy.
Roth SL; Audretsch W; Bojar H; Lang I; Willers R; Budach W
Strahlenther Onkol; 2010 Jun; 186(6):299-306. PubMed ID: 20495968
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive Review on the Surrogate Endpoints of Efficacy Proposed or Hypothesized in the Scientific Community Today.
von Minckwitz G; Fontanella C
J Natl Cancer Inst Monogr; 2015 May; 2015(51):29-31. PubMed ID: 26063882
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer.
Tanei T; Shimomura A; Shimazu K; Nakayama T; Kim SJ; Iwamoto T; Tamaki Y; Noguchi S
Eur J Surg Oncol; 2011 Feb; 37(2):155-61. PubMed ID: 21111561
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant endocrine therapy for breast cancer: more questions than answers.
Ellis MJ
J Clin Oncol; 2005 Aug; 23(22):4842-4. PubMed ID: 15998901
[No Abstract] [Full Text] [Related]
25. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant Therapy for HER2-positive Breast Cancer.
Wuerstlein R; Harbeck N
Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
[TBL] [Abstract][Full Text] [Related]
27. Response evaluation in HER2-positive mucinous breast carcinoma after neoadjuvant chemotherapy: Progressive disease clinically but complete response pathologically.
Xue B; Wang X; Zhang Y; Pei X
Asian J Surg; 2022 Nov; 45(11):2405-2406. PubMed ID: 35643896
[No Abstract] [Full Text] [Related]
28. Is radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy?
Daveau C; Savignoni A; Abrous-Anane S; Pierga JY; Reyal F; Gautier C; Kirova YM; Dendale R; Campana F; Fourquet A; Bollet MA
Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1452-9. PubMed ID: 20605368
[TBL] [Abstract][Full Text] [Related]
29. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
[TBL] [Abstract][Full Text] [Related]
30. High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy.
Zelnak AB; Nikolinakos P; Srinivasiah J; Jonas W; Pippas A; Liu Y; Li X; Torres M; O'Regan RM;
Clin Breast Cancer; 2015 Feb; 15(1):31-6. PubMed ID: 25065563
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant or adjuvant chemotherapy in early breast cancer?
Montemurro F; Nuzzolese I; Ponzone R
Expert Opin Pharmacother; 2020 Jun; 21(9):1071-1082. PubMed ID: 32237920
[TBL] [Abstract][Full Text] [Related]
32. Is there still a role for neoadjuvant therapy in breast cancer?
Shannon C; Smith I
Crit Rev Oncol Hematol; 2003 Jan; 45(1):77-90. PubMed ID: 12482573
[TBL] [Abstract][Full Text] [Related]
33. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
[TBL] [Abstract][Full Text] [Related]
34. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.
Powles TJ; Hickish TF; Makris A; Ashley SE; O'Brien ME; Tidy VA; Casey S; Nash AG; Sacks N; Cosgrove D
J Clin Oncol; 1995 Mar; 13(3):547-52. PubMed ID: 7884414
[TBL] [Abstract][Full Text] [Related]
35. [Efficacy analysis of THP-containing regimens as neoadjuvant and adjuvant chemotherapy for primary breast cancer].
Wang LZ; Ouyang T; Wang TF; Xie YT; Fan ZQ; Fan T; Lin BY; Li JF
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):143-6. PubMed ID: 22780935
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant taxanes in the treatment of non-metastatic breast cancer: a systematic review.
Trudeau M; Sinclair SE; Clemons M;
Cancer Treat Rev; 2005 Jun; 31(4):283-302. PubMed ID: 15916855
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study.
Sarid D; Ron IG; Sperber F; Stadler Y; Kahan P; Kovner F; Ben-Yosef R; Marmor S; Grinberg Y; Maimon N; Weinstein J; Yaal-Hahoshen N
Clin Drug Investig; 2006; 26(12):691-701. PubMed ID: 17274676
[TBL] [Abstract][Full Text] [Related]
38. Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials.
Tao Y; Klause A; Vickers A; Bae K; Ellis M
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):91-5. PubMed ID: 15994076
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of Hispanic women with lymph-node positive, HER2 positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab in Mexico.
Villarreal-Garza C; Soto-Perez-de-Celis E; Sifuentes E; Ruano S; Baez-Revueltas B; Lara-Medina F; Arce-Salinas C; Alvarado-Miranda A; Chavarri-Guerra Y; Caro-Sanchez C; Castañeda-Soto N; Bargallo-Rocha E; Mohar A
Breast; 2015 Jun; 24(3):218-23. PubMed ID: 25698148
[TBL] [Abstract][Full Text] [Related]
40. Are we HER-ting for innovation in neoadjuvant breast cancer trial design?
Snoj N; Bedard PL; de Azambuja E; Cardoso F; Piccart M
Breast Cancer Res; 2009; 11(1):201. PubMed ID: 19216727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
